Thoroughbred Financial Services LLC Purchases New Stake in Axon Enterprise, Inc $AXON

Thoroughbred Financial Services LLC acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,047 shares of the biotechnology company’s stock, valued at approximately $1,469,000.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares in the last quarter. Geode Capital Management LLC increased its holdings in Axon Enterprise by 5.9% in the second quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company’s stock valued at $1,713,332,000 after buying an additional 115,349 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Axon Enterprise by 53.8% in the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock worth $677,412,000 after acquiring an additional 330,213 shares during the period. Vestor Capital LLC grew its holdings in shares of Axon Enterprise by 438,636.3% in the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock worth $690,170,000 after acquiring an additional 833,409 shares during the period. Finally, Norges Bank purchased a new position in Axon Enterprise in the 2nd quarter valued at approximately $637,806,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and strong guidance — Axon reported Q4 revenue of ~$797M (+39% YoY) and non‑GAAP EPS $2.15, beating Street estimates; management issued FY26 growth guidance and a 2028 target of $6B in revenue, supporting upside expectations. PR Newswire: Axon reports Q4 2025
• Positive Sentiment: AI is accelerating demand — Management highlighted AI features across devices and software (body cams, evidence management, report drafting), which investors interpreted as boosting SaaS adoption and bookings momentum. Coverage noting the “AI supercharge” reaction: Investopedia: Axon AI story
• Positive Sentiment: Bookings/backlog and retention — Management disclosed a sizable increase in contracted bookings/backlog and a high net revenue retention (~125%), signaling both strong new sales and upsells from existing customers. This underpins longer‑term revenue visibility. MarketBeat: Q4 results & guidance deck
• Neutral Sentiment: Earnings call/transcript available — Investors can review management commentary and Q&A for nuance on federal spending, enterprise demand and AI rollout. Seeking Alpha: Q4 2025 transcript
• Neutral Sentiment: Short‑interest data flagged as anomalous — a February short‑interest entry shows 0 shares / NaN change (likely a reporting error); not meaningful for positioning until clarified.
• Negative Sentiment: Analysts trimmed price targets despite the beat — several firms cut PTs (UBS to $570/neutral; Barclays, Morgan Stanley, Piper reduced PTs but kept overweight views in many cases), which could cap upside and reflect lingering valuation/near‑term risk concerns. Benzinga: analyst PT cuts

Insider Buying and Selling at Axon Enterprise

In other news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the completion of the transaction, the president owned 249,502 shares of the company’s stock, valued at $137,874,805.20. This represents a 7.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $619.01, for a total transaction of $6,190,100.00. Following the completion of the transaction, the chief executive officer owned 3,100,997 shares in the company, valued at approximately $1,919,548,152.97. This trade represents a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 48,040 shares of company stock valued at $27,249,338. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $520.18 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The firm has a market cap of $41.05 billion, a PE ratio of 342.23, a P/E/G ratio of 13.33 and a beta of 1.48. The firm has a 50 day simple moving average of $539.22 and a 200-day simple moving average of $628.00. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.94%. Axon Enterprise’s revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.08 earnings per share. On average, equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AXON. Craig Hallum reissued a “buy” rating and issued a $820.00 target price on shares of Axon Enterprise in a report on Wednesday. Morgan Stanley decreased their price objective on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research report on Wednesday. Robert W. Baird set a $800.00 price objective on shares of Axon Enterprise in a research note on Wednesday. Citigroup restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday. Finally, Needham & Company LLC reduced their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $762.93.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.